Home › Encyclopedia › Thymosin Alpha-1: Research Status and Clinical Trial Data
Research / Unapproved

Thymosin Alpha-1: Research Status and Clinical Trial Data

Molecular formulaC129H215N33O55
Molecular weight3108.3 g/mol
Registered trials69
PubChem CID16130571

What thymosin alpha-1 is

Thymosin alpha-1 is a synthetic peptide (molecular formula C129H215N33O55) studied in clinical research settings. It does not have an approved drug label, and no FDA-sanctioned prescribing information exists for it. Any use outside of registered research protocols falls outside regulatory oversight.

Clinical trial footprint

Thymosin alpha-1 has been registered in 69 clinical trials. Among the sampled studies, a completed phase 3 trial evaluated it in combination with peg-interferon alfa-2a and ribavirin for chronic hepatitis C that had not responded to prior interferon and ribavirin therapy. A completed phase 1/phase 2 trial examined it alongside REP 2139 (REP 9AC') in patients with HBV infection. A separate phase 2 trial exploring an abscopal effect in metastatic small cell lung cancer was withdrawn before completion.

FAQ

Is thymosin alpha-1 FDA approved?
No. Thymosin alpha-1 does not have an approved FDA label or indication. It remains an investigational compound studied in clinical research settings only.
What conditions has thymosin alpha-1 been studied for?
Clinical trials sampled in available data have examined thymosin alpha-1 in chronic hepatitis C, HBV infection, and metastatic small cell lung cancer. These studies reflect research use and do not establish that the compound is effective or approved for any condition.
How many clinical trials involve thymosin alpha-1?
Available registry data lists 69 clinical trials involving thymosin alpha-1. These span different phases and conditions, with statuses ranging from completed to withdrawn.
What is the chemical identity of thymosin alpha-1?
Thymosin alpha-1 is a peptide with the molecular formula C129H215N33O55 and a molecular weight of approximately 3108.3. It is catalogued under PubChem CID 16130571.
Did the lung cancer trial of thymosin alpha-1 produce results?
No. The phase 2 trial investigating an abscopal effect for metastatic small cell lung cancer was withdrawn, meaning it did not proceed to generate results.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: ClinicalTrials.gov PubChem

Updated 2026-11-07